JPRN-UMIN000023267已完成未知
Post marketing prospective study of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection - Post marketing prospective study of daclatasvir and asunaprevir
Second department of internal mediceine, Wakayama medical university0 个研究点目标入组 100 人开始时间: 2016年7月21日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)pregnant woman 2)decompensated cirrhosis
研究者
相似试验
已完成
不适用
Early Post-marketing Study of Daclatasvir (Daklinza) in the Treatment of Chronic Hepatitis C (CHC) in AdultsHepatitis CNCT03181074Bristol-Myers Squibb10
撤回
不适用
Early Post-marketing Study of Daclatasvir (Daklinza®) + Asunaprevir (Sunvepra®) in the Treatment of Chronic Hepatitis C (CHC) in AdultsHepatitis CNCT03208322Bristol-Myers Squibb
终止
不适用
Study of Daclatasvir-based Therapy in Chinese Participants With Chronic Hepatitis C (CHC)Chronic Hepatitis CNCT03500562Bristol-Myers Squibb3
进行中（未招募）
1 期
A Study of an investigational treatment regimen of daclatasvir (DCV) + asunaprevir (ASV) + BMS-791325 in a fixed dose combination (the triple regimen) for 12 weeks for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection in non-cirrhotic subjectsHEPATITIS C VIRUSMedDRA version: 18.0Level: LLTClassification code 10072848Term: Hepatitis C virus genotype 1 positiveSystem Organ Class: 100000004848EUCTR2013-002468-20-FRBristol-Myers Squibb International Corporation472
进行中（未招募）
1 期
A Study of an investigational treatment regimen of daclatasvir (DCV) + asunaprevir (ASV) + BMS-791325 in a fixed dose combination (the triple regimen) with or without ribavirin (RBV) for 12 weeks for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection in subjects with compensated cirrhosisEUCTR2013-002458-66-FRBristol-Myers Squibb International Corporation300